Noridian decision extends reimbursement for freestanding centers to over half of U.S. states and territories
HAYWARD, Calif.–(BUSINESS WIRE)–#SCINTIX—RefleXion Medical today announced another Medicare Administrator Contractor (MAC), Noridian Healthcare Solutions, LLC has established accretive payment for SCINTIX® autonomous radiotherapy in freestanding centers in both of its jurisdictions at a level that reflects the cost of delivering this advanced therapy. This follows a recent decision by two other MACs in three jurisdictions covering southern and eastern states that also set payment rates above that of conventional radiotherapy for the company’s breakthrough SCINTIX therapy.
“We are buoyed by this latest reimbursement payment decision because it removes an important barrier to patient access,” said Todd Powell, president and CEO at RefleXion. “It also provides reassurance and support to freestanding center providers in over half of U.S. states and territories who strive to incorporate innovative treatments like SCINTIX therapy for their patients within their communities.”
Noridian, the latest MAC to assign payment for SCINTIX therapy, expands access for Medicare patients to an additional 16 states and U.S. territories including: Alaska, Arizona, California, Hawaii, Idaho, Montana, Nevada, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming, American Samoa, Guam, and the Northern Mariana Islands.
With more than 40 percent of U.S. cancer patients receiving radiation therapy in FSCs centers1, this decision by Noridian to establish reimbursement for patients treated in these states is critical to removing financial barriers to adoption for innovative treatment options.
SCINTIX therapy includes a unique pre-treatment procedure, called functional modeling, followed by up to five treatment sessions. Noridian assigned payment rates for the technical components of both procedures, and the professional component of the modeling procedure, which requires additional physician work. The professional payment also applies to procedures in the hospital outpatient department in their jurisdictions.
About RefleXion Medical
RefleXion is a privately held external-beam theranostic oncology company located in Hayward, Calif. It is the first and only company commercializing SCINTIX autonomous radiotherapy, an innovative technology that uses a single radiotracer injection to turn cancer cells into real-time biological beacons to guide treatment delivery. SCINTIX therapy is FDA-cleared for FDG-guided treatment of lung and bone tumors, including metastases. The RefleXion X2 platform is also cleared for conventional image-guided radiotherapy for solid tumors throughout the body. For more information, visit www.reflexion.com.
1 https://docs.house.gov/meetings/IF/IF14/20171108/106599/HHRG-115-IF14-Wstate-KavanaghB-20171108.pdf
Contacts
Media Contact:
[email protected]
+1-650-239-9070
Media Resources
